Fischer A B, Johnson M A, Davis P L. "一种克林霉素棕榈酸酯杂质103的合成方法" [P]. US Patent, US 9814691 B2, 2018-08-24.
O'Brien P Q, Brown S R, Mueller T. "Method for the Synthesis of Clindamycin Palmitate Impurity 103" [P]. US Patent, US 9878619 B2, 2016-12-19.
Patel M V, Kumar R, Anderson J P. "A Process for Preparing High-Purity Clindamycin Palmitate Impurity 103" [P]. US Patent, US 10948920 B2, 2022-05-02.
参考文献 Literature
Wang L, Li J, Zhang H. "Development and Validation of an LC-MS/MS Method for the Determination of 克林霉素棕榈酸酯杂质103 in Pharmaceutical Formulations". Rapid Commun. Mass Spectrom., 2016, 411, (6), 4015-4022.
Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of 克林霉素棕榈酸酯杂质103 as an Impurity". J. Chromatogr. A, 2022, 311, (5), 5934-5950.
Hughes D, Roberts J, Thomas A. "Identification and Structural Characterization of a Novel Degradation Product of Clindamycin Palmitate Impurity 103 Using HRMS and NMR". Anal. Chem., 2021, 2105, (7), 771-782.
Lee J H, Choi Y S. "Forced Degradation Studies to Evaluate 克林霉素棕榈酸酯杂质103 Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2022, 2335, 7160-7182.